Celera to Split from Applera

/0 Comments/in , , , , /by

Norwalk, CT 2/29/08—Applera has announced its Celera subsidiary, one of the company’s two tracking stocks, along with Applied Biosystems, will pursue a possible spin-off from Applera to become a separately traded public firm (see IBO 8/15/07). Celera provides diagnostic products and services. Holders of the Celera tracking stock would receive Celera shares in a one-for-one […]

Read more →

Instrument Firms Test Diagnostics Market

/0 Comments/in , , , , , , /by

Recent acquisitions have highlighted the evolving relationship of instrument companies and the molecular diagnostics market. Last month, QIAGEN acquired Digene, the largest provider of human papillomavirus (HPV) diagnostics tests, for $1.6 billion (see IBO 6/15/07). Earlier this year, Agilent acquired Stratagene for $246.2 million (see IBO 4/15/07). These developments follow acquisitions last year by Luminex […]

Read more →

Betting on Molecular Diagnostics, QIAGEN Buys Digene

/0 Comments/in , , , /by

Venlo, The Netherlands and Gaithersburg, MD 6/3/07—QIAGEN NV has agreed to acquire publicly listed molecular diagnostics firm Digene for approximately $1.6 billion, including $170 million in cash. QIAGEN will offer Digene stockholders $61.25 in cash per share, a 37% premium over Digene’s June 1 closing price, or 3.545 of QIAGEN stock. QIAGEN and Digene shareholders […]

Read more →